Bioneer

Bioneer FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bioneer (064550.KQ) as of Nov 5, 2026 is -112.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 126.85 % — a change of -188.83% (lower).

FCF Conversion

-112.69 %

YoY

-188.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bioneer is 2025 -112.69 % . FCF Conversion Rate (FCF/EBITDA) of Bioneer was 2024 126.85 % . It decreases by -188.83% lower compared to the previous year.

The Bioneer FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
133.93 KRW
Jan 1, 2019
127.79 KRW
Jan 1, 2020
71.14 KRW
Jan 1, 2021
40.49 KRW
Jan 1, 2022
-80.47 KRW
Jan 1, 2023
4.95 KRW
Jan 1, 2024
126.85 KRW
Jan 1, 2025
-112.69 KRW
The Bioneer FCF Conversion history
YEARFCF ConversionYoY
-112.69 %-188.83%
126.85 %+2,463.25%
4.95 %-106.15%
-80.47 %-298.73%
40.49 %-43.08%
71.14 %-44.33%
127.79 %-4.58%
133.93 %+145.12%
54.64 %-24.84%
72.69 %-1.24%
73.60 %+114.31%
34.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioneer Stock analysis

What does Bioneer do? BIONEER Corp. generates revenue through the sale of biotechnological products, primarily DNA reagents, molecular diagnostic kits, and related services. The company offers DNA and RNA amplification products, Oligo synthesis, gene synthesis services, gene and protein expression, genomics services, and human and veterinary diagnostics kits. It also sells DNA extraction, amplification, and quantitative analysis devices, along with equipment and supplies for biotechnology research. These products are sold to domestic and international markets, including America, China, Japan, India, and Africa, where they serve research institutions, diagnostic laboratories, and healthcare providers. The firm's revenue streams include DNA reagents, molecular diagnostic kits, and DNA diagnostic devices, which are used by customers in the biotechnology, healthcare, and veterinary sectors. DNA amplification products and gene synthesis services are key offerings for research-focused clients, while human and veterinary diagnostics kits target healthcare and animal health markets. Equipment and supplies for biotechnology research are sold to academic and commercial laboratories globally. BIONEER Corp. focuses on developing and selling specialized biotechnology products, with a strong emphasis on DNA and RNA-related technologies. Its product portfolio includes reagents, kits, devices, and services that cater to both research and diagnostic applications. The company's international presence in key markets like America, China, and Japan drives its revenue, with a significant portion coming from the sale of diagnostic kits and DNA analysis equipment. Bioneer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioneer stock

FCF Conversion Rate (FCF/EBITDA) of Bioneer is -112.69 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Bioneer changed from 126.85 % to -112.69 %, representing a -188.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bioneer since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bioneer with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bioneer

All Key Metrics — Bioneer